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Abstract ERM (Ezrin/Radixin/Moesin) proteins are cross-
linkers between plasma membrane proteins and the actin cyto-
skeleton, thereby involved in the formation of cell adhesion sites.
Earlier work showed that Ezrin links syndecan-2 to the actin
cytoskeleton. Here we provide evidence that the Ezrin N-termi-
nal domain binds to the syndecan-2 cytoplasmic domain with an
estimated KD of 0.71 WM and without the requirement of other
proteins. We also studied the regions in the syndecan-2 cyto-
plasmic domain implicated in the binding to Ezrin. By truncat-
ing the syndecan-2 cytoplasmic domain and by oligopeptide
competition assays we show that the Ezrin-binding sequence is
not located in the positively charged juxtamembrane region
(RMRKK), but in the neighboring sequence DEGSYD. We
therefore conclude that the consensus sequence for Ezrin binding
is unique among membrane proteins, suggesting a distinct reg-
ulation.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Ezrin/Radixin/Moesin (ERM) proteins were isolated as a
constituent of microvilli [1], in rat liver adherens junctions
[2,3], and as a heparin-binding molecule [4], respectively [5].
They function as crosslinkers between plasma membrane pro-
teins and the actin cytoskeleton [6^13]. Due to intramolecular
binding, ERM proteins are synthesized in a folded, inactive
state [14,15]. Upon activation by the Rho A pathway via Rho
kinase or phosphatidylinositol 4-phosphate 5-kinase [16] and
phosphatidylinositol 4,5-bisphosphate [17^20], they are un-
folded and undergo head-to-tail polymerization, thereby link-
ing transmembrane proteins to the actin cytoskeleton [21^23].
This process is important in targeting proteins to their desti-
nation [24^26] and in the transduction of growth signals [27].
Apart from direct binding to membrane proteins, ERMs
can also ful¢ll their crosslinker function via adapter proteins
such as ERM-binding phosphoprotein-50 or its isoform Naþ/
Hþ exchanger 3 (NHE3) kinase A regulatory protein. This
has been described for receptors such as NHE3 and L-adren-
ergic receptors, among others [7,28]. Various direct N-termi-
nal-binding partners for ERM protein family members such
as CD43, CD44, intercellular adhesion molecule 2 (ICAM-2)
[21,29,30], and the axon protein CAM L1 [31] have been
described. These proteins have no identical cytoplasmic do-
mains but share a region of positively charged amino acids
next to the plasma membrane, which is believed to be respon-
sible for binding [32].
Previous work from our laboratory showed that Ezrin re-
quires its N-terminal domain to link syndecan-2 to the actin
cytoskeleton [33]. Syndecans are cell surface heparan sulfate
proteoglycans which have been implicated in cell^cell and
cell^matrix adhesion, but also in other functions such as co-
receptors of growth factors and other enzymes, attachment
sites for viruses and as coordinators of interaction between
proteases and their speci¢c inhibitors [34^42]. Syndecans
have a large extracellular domain, a single transmembrane
span and a short (about 30 amino acids) cytoplasmic domain.
All syndecans have a cluster of positively charged amino acids
in the juxtamembrane region of the cytoplasmic tail [34^36]
similar to the sequence responsible for ERM binding in
CD43, CD44 and ICAM-2.
We present evidence that the binding of Ezrin to syndecan-
2 is direct and does not require the juxtamembrane region but
rather the sequence DEGSYD. We conclude that ERM pro-
teins can bind to several motifs in the cytoplasmic region of
distinct transmembrane proteins.
2. Materials and methods
2.1. Antibodies
Anti-N-Ezrin [43] and anti-Ezrin [22] (for C-Ezrin detection) were
produced as described elsewhere. The antibody anti-glutathione
S-transferase (GST) was from Santa Cruz Biotechnologies.
2.2. DNA constructions
Human Ezrin N- and C-terminal domains (amino acids 1^333 and
331^586 respectively) were subcloned into pGEX-2T expression vec-
tors [43] as described. To generate GST-syndecan-2 (cytoplasmic do-
main) fusion protein expression vector (A construct), the human syn-
decan-2 cytoplasmic domain was ampli¢ed by polymerase chain
reaction with oligonucleotides that introduced a BamHI site before
the ¢rst arginine and an EcoRI site after the stop codon and sub-
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cloned between the BamHI and EcoRI sites of pGEX-3X (Promega).
To delete the amino acids RMRKK (B construct) and the amino acids
RMRKKDEGSYD (E construct), the BamHI site was introduced
before the ¢rst and after the second aspartate respectively. Introduc-
ing premature stop codons generated the truncations of the last KE-
FYA amino acids (C construct) or FYA amino acids (D construct).
2.3. Protein production
GST-syndecan-2 (cytoplasmic domain) fusion proteins (A, B, C, D,
E constructs) were produced as follows. Expression vectors were
transformed into Escherichia coli BL-21 pLys bacteria. Cells were
grown until absorbance at 600 nm reached 0.6 and protein expression
was induced by addition of 0.5 mM isopropyl-L-D-thiogalactopyrano-
side (IPTG) for 70 min at 37‡C. Cells were lysed by freezing in bu¡er
(1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsul-
fonyl £uoride, 0.15 TIU/ml aprotinin, 10 Wg/ml leupeptin in phos-
phate-bu¡ered saline (PBS) pH 7.4) and sonication. The lysate was
supplemented with 1% Triton X-100 and clari¢ed at 20 000Ug. The
lysate was then mixed with Sepharose-glutathione beads (Sigma) for
30 min at 4‡C. The beads were washed in bu¡er (1 mM EDTA, 1 mM
DTT, 0.5% Triton X-100 in PBS pH 7.4) and the concentration and
purity of the bound proteins were evaluated by sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^PAGE) and Coomassie
staining.
Ezrin C- and N-terminal domains were produced as described in
Roy et al. [43]. Brie£y, expression vectors were transformed into E. coli
BL-21 pLys bacteria. Cells were grown until absorbance at 600 nm
reached 0.6 and protein expression was induced by addition of 0.5 mM
IPTG for 40 min at 30‡C. Cells were lysed by sonication in bu¡er and
the lysate was clari¢ed at 20 000Ug. The lysate was then mixed with
Sepharose-glutathione beads overnight at 4‡C. The beads were
washed in bu¡er and the bound protein was digested with 15 U
thrombin (Sigma T-3399) in bu¡er (100 mM NaCl, 2.5 mM CaCl2
in 50 mM Tris^HCl pH 7.4) for 2 h and recovered by elution. The
concentration and purity of the digested proteins were evaluated by
SDS^PAGE and Coomassie staining.
2.4. In vitro binding assays
GST-syndecan-2 (cytoplasmic domain) beads were mixed with
N- or C-Ezrin in 200 Wl of interaction bu¡er (100 mM NaCl, 0.25%
Tween 20, 1 mM MgCl2, 2 mM EGTA, 1 mM DTT in 50 mM Tris^
HCl pH 7.4) for 30 min at room temperature. The ¢nal protein con-
centrations were 1 WM GST-syndecan-2 (cytoplasmic domain) and
0.25^2 WM N- or C-Ezrin. The beads were then washed four times
in 1 ml of interaction bu¡er, boiled in SDS^PAGE loading bu¡er and
resolved. The bound N- or C-Ezrin was detected by Western blotting.
2.5. Determination of binding constants
The Western blots were quanti¢ed with the Molecular Analyst soft-
ware (Bio-Rad). The amount of bound N- or C-Ezrin was determined
Fig. 1. The N-terminal but not the C-terminal domain of Ezrin binds to the cytoplasmic domain of syndecan-2. A: Fusion protein GST-synde-
can-2 (cytoplasmic domain) immobilized on glutathione-Sepharose beads (1 WM) was incubated with the indicated concentrations of the N-ter-
minal or C-terminal domain of Ezrin (N-Ezrin or C-Ezrin). After washing, bound proteins were resolved by electrophoresis and bound N- or
C-Ezrin or immobilized GST fusion protein were detected by immunoblotting. Positive control (+) corresponds to 500 ng of pure N- or C-Ez-
rin. B: Dissociation constant for N-Ezrin binding to the cytoplasmic domain of syndecan-2 is 0.71 WM. The fractional saturation for N-Ezrin
binding to the syndecan-2 cytoplasmic domain was plotted versus N-Ezrin concentration and KD was calculated as described in Section 2
(n=6).
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by interpolation with known amounts of N- or C-Ezrin loaded in the
same gel. The fractional saturation (Y) was calculated from the ratio
mol bound N-Ezrin to mol GST-syndecan-2 (cytoplasmic domain).
The dissociation constant (KD) was calculated with the formula
3m=1/KD, where m is the slope of the Scatchard plot.
3. Results
3.1. Ezrin binds to syndecan-2 via its N-terminal domain in a
dose-dependent manner
Interaction between syndecan-2 and Ezrin has already been
described [33]. First, we studied the strength of this interac-
tion. The syndecan-2 cytoplasmic domain fused to GST and
Ezrin N- and C-terminal domains were produced in bacteria.
The Ezrin N-terminal domain bound syndecan-2 cytoplasmic
domain, but not GST, in a dose-dependent manner in vitro
(Fig. 1A). The dissociation constant for the binding (KD) was
0.71 WM (Fig. 1B). In contrast, the C-terminal domain of
Ezrin did not bind to syndecan-2, even at high concentrations.
These results suggest a direct interaction between syndecan-2
and Ezrin and support studies in vivo demonstrating that
both proteins co-localized and co-immunoprecipitated in
COS-1 cells [33].
3.2. Deletion of DEGSYD sequence abolishes binding between
syndecan-2 and N-Ezrin
The binding of deleted versions of syndecan-2 to the Ezrin
N-terminal domain was assayed in vitro (Fig. 2A) and com-
pared to that of the entire domain (Fig. 2B). Elimination of
the terminal KEFYA or FYA amino acids had no e¡ect on
the binding (Fig. 2B, constructs C and D respectively), sug-
gesting that the sequence involved in the binding to syntenin
[44] is not required. In addition, the elimination of the
RMRKK motif described to be an ERM-binding motif in
other molecules increased binding (Fig. 2B, construct B). In
contrast, further deletion of the motif DEGSYD abolished
binding (Fig. 2B, construct E). These results suggest that the
motif of the syndecan-2 cytoplasmic domain, which is respon-
sible for Ezrin binding, is located in the sequence DEGSYD.
3.3. An oligopeptide with the sequence DEGSYDL competes
for the binding of N-Ezrin to syndecan-2 cytoplasmic
domain
In order to con¢rm the results described above, six oligo-
Fig. 2. N-Ezrin requires the DEGSYD sequence in the syndecan-2
cytoplasmic domain for binding. N-Ezrin binding (arbitrary units)
to GST, to complete syndecan-2 cytoplasmic domain (A), or to
truncated versions corresponding to amino acids 6^32 (B), 1^27 (C),
1^29 (D) or 12^32 (E) of the syndecan-2 cytoplasmic domain
(n=3).
Fig. 3. The peptide DEGSYDL competes with N-Ezrin for binding to the syndecan-2 cytoplasmic domain. B: The indicated peptides encom-
passing the entire sequence of the syndecan-2 cytoplasmic domain (A) were added to compete with fusion protein GST-syndecan-2 (cytoplasmic
domain) immobilized on glutathione-Sepharose beads (1 WM) for binding to the N-terminal domain of Ezrin (1 WM). The bound N-Ezrin at
the indicated concentration of peptide was detected by immunoblotting (B). The fractional saturation for the binding is plotted in C. A repre-
sentative experiment of two is shown.
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peptides (seven or eight amino acids) encompassing the entire
syndecan-2 cytoplasmic domain were added to the in vitro
binding assays in order to compete for binding (Fig. 3A).
At 20 WM, neither the random peptide (6) nor peptides 1, 3,
4 or 5 had any e¡ect on the protein interaction (Fig. 3B,C).
The only peptide that signi¢cantly inhibited the interaction
between Ezrin and syndecan-2 contained the sequence DEG-
SYDL (peptide 2). Although the inhibitory e¡ect of peptide 2
was weak at 20 WM, it inhibited the interaction between syn-
decan-2 and N-Ezrin completely at 200 WM. None of the
other peptides had any e¡ect on the syndecan-2/Ezrin inter-
action at this concentration.
4. Discussion
Ten years ago, syndecans were considered a mere ‘multi-
purpose glue’ in the adhesion of cells to the extracellular ma-
trix [45,46]. Recently, many groups have focused their interest
on syndecans due to recent ¢ndings of their participation in
downstream signaling processes [37,47]. In an earlier study we
reported the ability of Ezrin to link syndecan-2 to the actin
cytoskeleton [33]. Here we show that the N- but not the
C-terminal region of Ezrin binds to syndecan-2 without the
requirement of accessory proteins. This binding is dose-depen-
dent with an estimated dissociation constant (KD) of 0.71 WM.
These ¢ndings are consistent with the ability of ERM proteins
to bind transmembrane proteins via their N-terminal domain
and to link them to the actin cytoskeleton by the C-terminal
domain.
ERM proteins bind to several transmembrane proteins such
as CD43, CD44 and ICAM-2 [29,30], which do not share
common motifs in their cytoplasmic tails. Nevertheless, bind-
ing was localized to a cluster of positively charged amino
acids in the juxtamembrane region of these proteins. Compar-
ison of the cytoplasmic domain of syndecan-2 with the pro-
teins described above showed that it contains the motif
RMRKK in the juxtamembrane region. Surprisingly, we ob-
served that the sequence DEGSYD was the only requirement
for binding. These data were con¢rmed by experiments with
oligopeptides competing for Ezrin binding. In contrast, a syn-
decan-2 cytoplasmic domain lacking the positively charged
amino acid cluster bound more strongly to N-Ezrin. This
might be explained by easier accessibility to the binding motif
after deletion of the RMRKK motif. A recent publication
showed that the binding motif of ICAM-3 is located in a
juxtamembrane region of ICAM-3 containing the sequence
GSY, present in the syndecan-2 DEGSYD motif [25,48].
Nevertheless, the rest of the region responsible for N-Ezrin
binding to syndecan-2 and ICAM-3 is distinct.
In syndecans, serine and tyrosine phosphorylation have
been described [49^53]. For syndecan-2, Oh et al. reported
that serine 197 and 198 in the cytoplasmic region can be phos-
phorylated by protein kinase C. In this context, phosphoryla-
tion events of the serine and tyrosine residues of the GSY
motif might modulate Ezrin binding. This theory seems to
be particularly interesting given that syndecan clustering
also depends on serine phosphorylation [50].
The phosphorylation state of serine and tyrosine residues in
the cytoplasmic domain [55] and the oligomerization state of
syndecan-2 might also in£uence binding, as is the case for its
interaction with the EphB receptor in neurons [54]. This
would endow the cell with an abundance of regulation possi-
bilities for the binding of ERM to membrane proteins, there-
by participating in the regulation of cell shape and behavior.
Finally, it should be mentioned that the motif DEGSY is
conserved among all four syndecans, D-syndecan and syn-
decan from Caenorhabditis elegans [36]. This means that,
although it was here only demonstrated for syndecan-2, it is
possible that all syndecans are able to bind to N-Ezrin. Fur-
ther experiments should be performed in order to address this
question.
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